MannKind (MNKD) Stock Price, News & Analysis

Company Overview

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S. Food and Drug Administration (FDA) approval in 2014 and is marketed directly by MannKind in the United States. The company initially entered into a co-promotion agreement with Sanofi for U.S. distribution of Afrezza, though that partnership concluded in 2016, prompting MannKind to establish its own commercial infrastructure. Beyond Afrezza, MannKind continues to evaluate additional indications for its Technosphere platform, including therapies for pulmonary hypertension and other conditions where rapid drug uptake via inhalation may offer clinical benefits.

Founded in 1991 by biomedical entrepreneur Dr. Alfred E. Mann, MannKind is headquartered in Westlake Village, California. Its leadership team includes President and Chief Executive Officer Michael Castagna, who has guided the company’s commercial operations and pipeline development since 2015. MannKind’s research and development activities are conducted primarily in the United States, with plans to seek regulatory approvals and partnerships in international markets as part of its long‐term growth strategy.

Through its focus on inhalation science and patient‐centric product design, MannKind aims to broaden the applications of its Technosphere technology beyond diabetes care. The company remains committed to advancing novel therapies that leverage the lung as a route of drug delivery, potentially transforming treatment paradigms for metabolic and respiratory diseases.

Key Stats

• Today's Range: $3.40 to $4.29
• 50-Day Range: $2.28 to $5.57
• 52-Week Range: $2.23 to $6.51
• Volume: 12.16 million shs
• Average Volume: 5.21 million shs
• Market Capitalization: $1.26 billion
• P/E Ratio: 202.35
• Dividend Yield: N/A
• Price Target: $8.69
• Consensus Rating: Moderate Buy

MannKind Stock Analysis - MarketRank™

MannKind scored higher than 75% of companies evaluated by MarketBeat, and ranked 158th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MannKind has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

MannKind has a consensus price target of $8.69, representing about 203.8% upside from its current price of $2.86.

Amount of Analyst Coverage

MannKind has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MannKind are expected to grow in the coming year, from ($0.02) to $0.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MannKind is 143.07, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of MannKind is 143.07, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.02.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.83% of the float of MannKind has been sold short.

Short Interest Ratio / Days to Cover

MannKind has a short interest ratio ("days to cover") of 8.82.

Change versus previous month

Short interest in MannKind has recently increased by 0.38%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MannKind does not currently pay a dividend.

Dividend Growth

MannKind does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.74

News Sentiment

MannKind has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for MannKind this week, compared to 4 articles on an average week.

Search Interest

9 people have searched for MNKD on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.

MarketBeat Follows

7 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $259,000.00 in company stock, which represents 0.0293% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, MannKind insiders have bought more of their company's stock than they have sold. Specifically, they have bought $259,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.60% of the stock of MannKind is held by insiders.

Percentage Held by Institutions

49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MNKD Stock Analysis - Frequently Asked Questions

How have MNKD shares performed this year?

MannKind's stock was trading at $5.67 at the start of the year. Since then, MNKD shares have decreased by 49.6% and is now trading at $2.86.

How were MannKind's earnings last quarter?

MannKind Corporation (NASDAQ:MNKD) announced its quarterly earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.04. The company's revenue was up 45.8% on a year-over-year basis.
Read the conference call transcript.

Who are MannKind's major shareholders?

MannKind's top institutional investors include 180 Wealth Advisors LLC (1.39%), TSP Capital Management Group LLC (1.08%), Bank of New York Mellon Corp (0.27%) and 1492 Capital Management LLC (0.18%). Insiders that own company stock include Michael Castagna, Stuart A Tross, David Thomson, Steven B Binder and Sanjay R Singh.
View institutional ownership trends.

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Cos (BHC), Intel (INTC) and Netflix (NFLX).

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MNKD
• CIK: 899460
• Web: www.mannkindcorp.com
• Phone: (818) 661-5000
• Fax: 661-775-2081
• Employees: 400
• Year Founded: 1991

Price Target and Rating

• Average Price Target for MannKind: $8.69
• High Price Target: $15.00
• Low Price Target: $3.50
• Potential Upside/Downside: +107.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.02
• Trailing P/E Ratio: 171.59
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.86 million
• Net Margins: 1.68%
• Pretax Margin: 0.40%
• Return on Equity: -11.21%
• Return on Assets: 1.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.70
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $348.97 million
• Price / Sales: 3.71
• Cash Flow: $0.09 per share
• Price / Cash Flow: 45.41
• Book Value: ($0.17) per share
• Price / Book: -24.67

Miscellaneous

• Outstanding Shares: 308,800,000
• Free Float: 300,767,000
• Market Cap: $1.30 billion
• Optionable: Optionable
• Beta: 1.04